By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.)  



New York City  New York    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Completion Of Enrollment In The Phase III Confirmatory Study of Kiacta™ For The Treatment Of AA Amyloidosis 5/28/2014 9:18:38 AM
Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Engagement Of Financial Advisor To Explore Sale Of KIACTA™, An Experimental Drug In Phase 3 Development For The Treatment Of AA Amyloidosis 5/7/2014 10:36:07 AM
Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Licence Agreement With Mount Sinai For KIACTATM In Sarcoidosis 5/2/2014 11:04:51 AM
Celtic Therapeutics Rebrands as Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) 3/11/2013 10:57:34 AM
Celtic Therapeutics Announces the Appointment of New Partner 10/29/2012 6:58:58 AM
Celtic Therapeutics Pledges $50 Million to Establish ADC Therapeutics, New Company Will Develop Antibody-Drug Conjugates 3/26/2012 7:29:25 AM
Resolvyx Pharmaceuticals, Inc. and Celtic Therapeutics Enter Final Agreement in Ophthalmology 1/10/2011 6:23:25 AM
Resolvyx Pharmaceuticals, Inc. and Celtic Therapeutics Ink Dry Eye Deal 10/26/2010 7:58:47 AM
Celtic Therapeutics and Spirogen Limited Release: Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer 9/15/2010 12:04:50 PM
BELLUS Health and Celtic Therapeutics Enter Agreement Worth $20 Million for Drug candidate KIACTA(TM) 4/30/2010 1:08:14 PM
12
//-->